Anglo Asian Mining PLC (AIM:AAZ, OTC:AGXKF) expects to produce 54,000 to 58,000 gold equivalent ounces (GEOs) in 2022, the Azerbaijan-focused company said alongside its first-half results.
The copper, gold, and silver miner produced 28,772 GEOs in the first half, down from 32,171 ounces in the year-earlier period, due to lower gold grades from its Gedabek operation.
Diversified Energy Company PLC (LSE:DEC, OTCQX:DECPF) announced it has been given the ESG Investing ‘Best Sustainability Reporting Award’ for 2022, recognising its documentation for 2021.
The company, in a statement, said that the award reflects “the company's commitment to incorporate sustainability into the fabric of its financing and operating strategies, and highlights the company's commitment to ESG reporting transparency within its sustainability and annual reports.”
Reabold Resources PLC (AIM:RBD) has completed the acquisition of working interests in all the non-Victory (P2596) licences within the Corallian Energy portfolio, being: P2396, P2464, P2493, P2504 and P2605 (all at 100% working interest) and P2478 (36% working interest). Reabold yesterday agreed to sell its stake in Victory to an unnamed oil major for £12.7mln net.
Open Orphan PLC (AIM:ORPH, OTC:OPORF) confirmed it is aware of allegations of potential insider dealing by a private individual unconnected to the company and is co-operating with the Irish authorities investigating the case. Investors were told: “The board of Open Orphan is satisfied that there are no implications for the company in the resolution of this allegation and confirms that no employee, executive, director or anyone connected with the company had any involvement whatsoever in this matter nor are they suspected of any wrongdoing.”
Roquefort Therapeutics PLC has confirmed that application has been made to the Financial Conduct Authority (FCA) and the London Stock Exchange (LSE) for a total of 57,249,998 new ordinary shares in the company, comprising 50,000,000 consideration shares and 7,249,998 placing shares of £0.01 each, to be admitted to trading on the LSE's main market, with admission to take place at 8.00am tomorrow, Friday, September 15, 2022. Completion of the acquisition of Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines, and the related placing will become effective on admission. The prospectus and further information on the company can be found on Roquefort Therapeutic's website.
Mode Global Holdings PLC, the LSE-listed Fintech Group, announced that it has received and accepted notices resulting in the conversion of an aggregate of £29,160.24 principal amount of its loan notes, resulting in the issuance of 914,461 new ordinary shares of 1p each in the capital of the company at a conversion price of 0.0319p per share.